AI assistant
Sending…
Niagen Bioscience, Inc. — Director's Dealing 2018
May 16, 2018
32418_dirs_2018-05-16_8cea9ccb-3260-40be-ac6b-41313db44c92.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-05-15
Reporting Person: Jaksch Frank L Jr (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-15 | Common Stock | P | 5500 | $3.61 | Acquired | 207057 | Direct |
| 2018-05-16 | Common Stock | P | 4300 | $3.56 | Acquired | 211357 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 2075052 | Indirect |
More from Niagen Bioscience, Inc.
Transaction in Own Shares
2026
Jul 10
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 29
Capital/Financing Update
2026
Jun 26
Call Transcript
2026
Jun 11
Call Transcript
2026
May 6
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Mar 19
Call Transcript
2026
Mar 4
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24